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Editorial
Antimicrobial resistance (AMR) is one of the world’s 
most pressing public health threats. It increases the 
cost of health care through longer duration of illness 
and hospital stays,1 additional tests,1 and the need 
for more expensive drugs.2 Around 700,000 people 
die of resistant infections every year globally.3 It has 
been projected that between now and 2050, AMR 
will result in around 10 million deaths with an 
associated economic cost, incurred by lost global 
production, of 100 trillion USD.3 
AMR refers to the ability of a microorganism 
to stop an antimicrobial (such as an antibiotic, 
antiviral or antimalarial) from working against it. 
As a consequence of AMR, standard treatments 
become ineffective, and infections persist and 
may spread to others. The impact of AMR is 
far-reaching and equates to the situation before the 
discovery of antibiotics, when even small infections 
were difficult, or very often impossible to treat, and 
medical procedures too risky to perform due to the 
potential of untreatable infection. 
According to the WHO, Southeast Asia is at the 
highest risk globally for the emergence and spread of 
AMR, predominantly due to the inappropriate use of 
antibiotics and weak systems of governance in health 
and agriculture.4,5 Excessive use of antibiotics for upper 
respiratory tract infections (URTI), where infection is 
commonly caused by a virus, is of particular concern 
in the region.6 A review by the WHO of studies 
published between 1990-2006 shows that between 
40%-60% of viral URTI cases in South East Asian 
countries were treated with antibiotics,7 with the rate 
significantly higher in private facilities compared 
to public.7 Common drivers of inappropriate use 
of antibiotics include poor knowledge, perceived 
patient demand, economic incentives, pressure from 
pharmaceutical marketing, unstable drug supply, 
lack of regulation and enforcement, particular social 
and cultural norms around medicine use, and health 
seeking preferences.8-11 
In 2011, health ministers in the Southeast 
Asian region adopted the Jaipur Declaration on 
AMR, calling for comprehensive action against the 
irrational use of antibiotics.12 Most recently, the 
Berlin declaration by G20 health ministers in May, 
2017 recognised the increasing threat of AMR and 
outlined various measures to address it.13 The region’s 
member states are currently implementing national 
action plans to tackle AMR.14 Indonesia’s National 
Action Plan on Antimicrobial Resistance (NAP 
AMR) was shared at the WHO General Assembly 
in May, 2017.15 Key supply-side initiatives of NAP 
AMR include (i) regulation of the production and 
distribution of antibiotics (e.g. coordination with 
the drug regulatory authority to develop regulations 
and quality checklists for the import, manufacture, 
quality, distribution, market authorization, 
advertising, and inspection of antimicrobial agents; 
and the promotion of investment in developing 
new medicines, diagnostic tools, vaccines and other 
interventions);16,17 (ii) AMR control programmes 
in public hospitals (e.g. linking the AMR control 
activities with hospital accreditation systems and 
training healthcare workers and staff in infection 
prevention control procedures and guidelines;17,18 
and (iii) hospital surveillance (e.g. scrutiny of 
antimicrobial prescribing, use, resistance, and 
monitoring hospital acquired infection).16,17 On 
the demand side, several awareness campaigns 
and training programmes have also been rolled 
out to improve knowledge about AMR among 
community groups, professional and government 
organisations, and journalists through platforms 
such as social media, workshops, and seminars.16,17,19 
These various initiatives are still in their infancy 
and to our knowledge, their impact is yet to be 
comprehensively evaluated. 
A recent systematic review of the impact 
of interventions to promote more effective 
use of antibiotics in low- and middle-income 
countries (LMICs) highlights the importance of 
improving the availability of diagnostic testing; 
providing dedicated education on AMR for both 
healthcare providers and the wider public; and 
strengthening (inter)national agencies responsible 
for the enforcement of regulations and auditing 
of the production, distribution and dispensing of 
antibiotics.20 Current evidence and policies for 
action on AMR focus heavily on the public sector. 
This is despite the fact that private drug sellers−
which typically include pharmacies, drug stores, 
general stores and itinerant vendors−are often 
the first point of contact and a major source of 
medicines and care in LMICs.21,22 For example, in 
Indonesia, 93% of patients are reported to obtain 
their antibiotics from these providers.23 Data from 
the Indonesian Ministry of Health shows that there 
are at least 26,658 licensed community pharmacies 
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and 13,477 licensed drugstores across the country’s 
34 provinces.24 In addition, there are at least 95,000 
unlicensed outlets, consisting of 5,000 drug stores 
and 90,000 kiosks across the country.25 These 
private providers are often preferred because they 
are accessible, convenient and reliable sources 
of affordable medicines,26 but they also tend to 
be unregulated and staffed by largely untrained 
personnel.21
The regulation and control of antibiotic use by 
private drug sellers is challenging. In Indonesia, 
antibiotics should only be dispensed by licensed 
pharmacists. Licenses for pharmacies are issued by 
the local district authority and involve submitting 
qualification and accreditation documents to 
the District Health Office (DHO), inspection of 
the facilities by the DHO and Food and Drug 
Administration (FDA) and subsequent processing 
of license applications by the DHO and FDA. In 
reality overall market control is weak25,27 with many 
unlicensed drug stores freely selling antibiotics.27-30 
This situation is not unique to Indonesia with 
studies showing that antibiotics are widely available 
from unlicensed village grocers or drugstores in 
Thailand, Cambodia and Vietnam.31-33 
Another regulation designed to encourage 
appropriate use of antibiotics by private drug sellers 
in Indonesia is the dispensing of prescription-
only antibiotics.34 In Indonesia and many other 
LMICs,35 this regulation is poorly implemented and 
enforced.21,27,36-39 For example, it has been estimated 
that around 86% of Indonesians currently obtain 
antibiotics from private drug sellers without a 
prescription and without adequate information and 
history gathering.21,37,38 Concerns have also been 
raised in Indonesia about the repackaging of larger 
and often cheaper units of antibiotics without any 
label,27 and the dispensing of poor quality antibiotics 
by community pharmacies, shops and kiosks.27 
Studies of private drug sellers in other LMICs have 
reported the dispensing of expired antibiotics40 and 
the provision of incomplete or shorter treatment 
courses, particularly in the case of patients who are 
thought to be too poor to afford a complete dose.40,41 
The private sector has been an overlooked but 
major source of AMR in many LMICs, including 
Indonesia. Private drug sellers such as community 
pharmacies and drug stores therefore have a major 
part to play in educating patients, rationalising 
antibiotic use, and stopping antibiotic sales 
without a prescription. Drafting new laws and 
regulations to govern the private sector is, however, 
unlikely to provide a comprehensive solution to 
the problem of AMR.42 AMR research must be 
broadened to include the evaluation of multi-
faceted interventions that better reflect the complex 
incentives and preferences of private drug sellers 
and their clients. This evidence is urgently needed 
as countries like Indonesia finalise their National 
Action Plans and begin rolling out AMR related 
activities. 
REFERENCES
1. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical 
and economic burden of antimicrobial resistance. Expert 
Review of Anti-infective Therapy. 2008;6(5):751-63.
2. Hawkey PM. The growing burden of antimicrobial 
resistance. Journal of Antimicrobial Chemotherapy. 
2008;62(suppl_1):i1-i9.
3. O'Neil J. Review on antimicrobial resistance. Tackling 
drug resistant infections globally: final report and 
recommendations.; 2016.
4. Chereau F, Opatowski L, Tourdjman M, Vong S. Risk 
assessment for antibiotic resistance in South East Asia. 
BMJ. 2017;358.
5. Holloway KA, Kotwani A, Batmanabane G, Puri M, 
Tisocki K. Antibiotic use in South East Asia and policies to 
promote appropriate use: reports from country situational 
analyses. BMJ. 2017;358.
6. Teng CL. Antibiotic prescribing for upper respiratory 
tract infections in the Asia-Pacific region: A brief 
review. Malaysian family physician : the official journal 
of the Academy of Family Physicians of Malaysia. 
2014;9(2):18-25.
7. World Health Organization. Medicines use in primary 
care in developing and transitional countries Fact Book 
summarizing results from studies reported between 1990 
and 2006. 2009.
8. McKay R, Mah A, Law MR, McGrail K, Patrick DM. 
Systematic Review of Factors Associated with Antibiotic 
Prescribing for Respiratory Tract Infections. Antimicrobial 
Agents and Chemotherapy. 2016;60(7):4106.
9. Radyowijati A, Haak H. Determinants of Antimicrobial 
Use in the Developing World. 2002.
10. Tangcharoensathien V, Chanvatik S, Sommanustweechai 
A. Complex determinants of inappropriate use of 
antibiotics. Bulletin of the World Health Organization. 
2018;96(2):141-4.
11. Radyowijati A, Haak H. Improving antibiotic use in low-
income countries: an overview of evidence on determinants. 
Social Science & Medicine. 2003;57(4):733-44.
12. World Health Organization Regional Office for South-East 
Asia. Jaipur declaration on antimicrobial resistance. . 2011.
13. G20 Health Ministers. Berlin Declaration of the G20 
Health Ministers: Together Today for a Healthy Tomorrow. 
Germany2017.
14. Dr Poonam Khetrapal Singh. Speech of the Regional 
Director: Workshop on National Action Plan on 
Antimicrobial Resistance for Developing Countries: 
Focusing on Resistance Emanating from Antibiotic Use 
in Food Animals. New Delhi, India: 34th session of WHO 
South-East Asia Advisory Committee on Health Research, 
World Health Organization 2016.
15. Parathon H, Kuntaman K, Widiastoety TH, Muliawan 
BT, Karuniawati A, Qibtiyah M, et  al. Progress towards 
antimicrobial resistance containment and control in 
Indonesia. BMJ. 2017;358.
16. Yuliati D. Guidelines on Implementation of Antimicrobial 
Resistance Program in Indonesia (Landasan Pelaksanaan 
Program Pengendalian Resistensi Antimikroba di 
Indonesia). Simposium Nasional Upaya Peningkatan 
Kesadaran Pencegahan Penyakit dan Penggunaan 
Antimikroba yang Baik dan Benar :“More Protection, Less 
Antimicrobial”; Jakarta2018.
17. The Indonesian Ministry of Health. National Action Plan 
Antimicrobial Resistance Indonesia 2017-2019. 2017.
81Published by DiscoverSys | Public Health and Preventive Medicine Archive 2018; 6(2): 79-81 | doi: 10.15562/phpma.v6i2.187
EDITORIAL
18. Indonesian Ministry of Health. Ministry of Health 
Regulation number 8 2015 Regarding Antimicrobial 
Resistant Control at Hospital Settings. 2015.
19. Indonesian Ministry of Health. Gema Cermat 2017 
[Available from: http://farmalkes.kemkes.go.id/category/
gemacermat/#.XAo5rNszb3g.
20. Cox JA, Vlieghe E, Mendelson M, Wertheim H, Ndegwa L, 
Villegas MV, et  al. Antibiotic stewardship in low- and 
middle-income countries: the same but different? Clinical 
Microbiology and Infection. 2017;23(11):812-8.
21. Chee G, Borowitz M, Barraclough A. Private Health Care 
Sector in Indonesia. Bethesda, MD: Abt Associates Inc; 
2009.
22. The Indonesian Ministry of Health. Riset Kesehatan Dasar 
(Riskesdas) 2013. 2013.
23. World Health Organization. Antibiotic Resistance: Multi-
county Public Awareness Survey. 2015.
24. Indonesian Ministry of Health. Mapping of 
Pharmaceutical Facilities 2013 - 2016 (Aplikasi 
Pemetaan Sarana Kefarmasian 2013-2016) Jakarta 2017 
[Available from: http://apif.binfar.depkes.go.id/index.
php?req=view_services&p=pemetaanIndustriFarmasi.
25. World Bank. Pharmaceuticals : why reform is needed 
(English). Indonesia health sector review : policy and 
discussion notes. Washington, DC: World Bank; 2009.
26. Goodman C, Kachur SP, Abdulla S, Bloland P, Mills A. 
Drug shop regulation and malaria treatment in Tanzania—
why do shops break the rules, and does it matter? Health 
policy and planning. 2007;22(6):393-403.
27. Hadi U, van den Broek P, Kolopaking EP, Zairina N, 
Gardjito W, Gyssens IC. Cross-sectional study of availability 
and pharmaceutical quality of antibiotics requested with 
or without prescription (Over The Counter) in Surabaya, 
Indonesia. BMC infectious diseases. 2010;10:203.
28. Editor Kompas. Jual Obat Tanpa Resep, Tiga Pemilik Toko 
Obat Ditangkap. Kompas. 2009.
29. Amaluddin. Dinkes akan Datangi Apotek Jual Bebas 
Antibiotik. Metrotvnews. 2015.
30. Baskoro D. Waspada Resistensi Antibiotik, Ketahui 
Fungsinya Sebelum Dikonsumsi. Okezone. 2016.
31. Arparsrithongsagul S, Kulsomboon V, Zuckerman  IH. 
Multidisciplinary Perspective Intervention With 
Community Involvement to Decrease Antibiotic Sales 
in Village Groceries in Thailand. Asia Pacific Journal of 
Public Health. 2015;27(2):NP2480-NP8.
32. Om C, Daily F, Vlieghe E, McLaughlin JC, McLaws M-L. 
Pervasive antibiotic misuse in the Cambodian community: 
antibiotic-seeking behaviour with unrestricted access. 
Antimicrobial resistance and infection control. 2017;6:30-.
33. Okumura J, Wakai S, Umenai T. Drug utilisation and 
self-medication in rural communities in Vietnam. Social 
Science & Medicine. 2002;54(12):1875-86.
34. Presiden Republik Indonesia. Peraturan Pemerintah 
Republik Indonesia Nomor 51 Tahun 2009 tentang 
pekerjaan kefarmasian. Jakarta2009.
35. Sakeena MHF, Bennett AA, McLachlan AJ. Non-
prescription sales of antimicrobial agents at community 
pharmacies in developing countries: a systematic 
review. International Journal of Antimicrobial Agents. 
2018;52(6):771-82.
36. The Indonesian Ministry of Health. 86,10% masyarakat 
di Indonesia mendapatkan antibiotik tanpa resep dokter 
2018 [Available from: https://twitter.com/KemenkesRI/
status/1075669370 733350914.
37. Puspitasari HP, Faturrohmah A, Hermansyah A. Do 
Indonesian community pharmacy workers respond to 
antibiotics requests appropriately? Tropical medicine & 
international health : TM & IH. 2011;16(7):840-6.
38. Brata C, Marjadi B, Schneider CR, Murray K, Clifford RM. 
Information-gathering for self-medication via Eastern 
Indonesian community pharmacies: a cross-sectional 
study. BMC Health Serv Res. 2015;15:8.
39. Kotwani A, Wattal C, Joshi PC, Holloway K. Irrational use 
of antibiotics and role of the pharmacist: an insight from a 
qualitative study in New Delhi, India. Journal of Clinical 
Pharmacy and Therapeutics. 2012;37(3):308-12.
40. Kotwani A, Wattal C, Joshi PC, Holloway K. Irrational use 
of antibiotics and role of the pharmacist: an insight from a 
qualitative study in New Delhi, India. J Clin Pharm Ther. 
2012;37(3):308-12.
41. Barker AK, Brown K, Ahsan M, Sengupta S, Safdar N. 
What drives inappropriate antibiotic dispensing? A mixed-
methods study of pharmacy employee perspectives in 
Haryana, India. BMJ open. 2017;7(3).
42. Asharina I. Resistensi Antibiotic di Indonesia - Tak Usah 
Dulu Bermain Undang Undang. Bandung Institute of 
Technology 2016.
This work is licensed under a Creative Commons Attribution
